Veradermics Q2 net loss $23.5M; positive Phase 2 female hair-loss data, cash $819.9M

Veradermics, Inc

Q2 2026 net loss $23.5M vs $15.6M YoY; R&D $18.6M (up $4.3M), G&A $10.9M (up $9.2M).
Phase 2 Study 207: mean TAHC increase 22.7 (QD) and 23.3 (BID) hairs/cm² at Month 6; 88.9%/90.0% improved on AAIRS.
Completed enrollment of Phase 2/3 Study 306 (556 female PHL patients); topline expected 1H27.
Phase 3 Study 304 topline and 12-month Study 302 data both anticipated in 2H26.
Cash $819.9M as of June 30, 2026; $472M raised in May 2026, funding into 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.